This Employee Appreciation Day, we express our gratitude to our team for its unwavering dedication and hard work advancing new medicines for I&I patients. The team’s commitment to Triveni’s shared values helps shape our culture, and we are thankful every day for their dedication!
关于我们
Triveni Bio is a biotech company pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders. The company’s approach establishes proof-of-concept at the earliest stages of drug development. Through a strong understanding of genetics and mechanistic biology, our pipeline is powered for indication expansion where we know we can have the most impact. To learn more, visit www.triveni.bio.
- 网站
-
https://www.triveni.bio
Triveni Bio的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Watertown，MA
- 类型
- 私人持股
地点
-
主要
获取路线
99 Coolidge Avenue
US，MA，Watertown，02472
Triveni Bio员工
动态
-
Triveni Bio uses human genetics to support the development of immunological and inflammatory diseases. This Rare Disease Day, Triveni Bio was proud to support Mission: Cure’s efforts to develop treatments for pancreatitis, including hereditary forms.?Learn more about our work at https://triveni.bio/.
A huge thank you to the Triveni Bio team for their incredible support of Mission: Cure! In honor of Rare Disease Day, Triveni Bio hosted an employee fundraiser benefiting Mission: Cure, raising an unbelievable $14,655! Not only did proceeds from their auction support our organization but many team members and community members contributed personally as well. We are grateful to partner with such a dedicated team that believes in our mission. Together, we are making strides toward a cure!
-
Today represents a significant milestone for Triveni as we close a $115 Million Series B Financing – led by Goldman Sachs Alternatives – to expand our pipeline of novel therapies for I&I disorders like #atopicdermatitis. Read more: https://bit.ly/4epr5GN Learn more about Triveni: https://triveni.bio/ #biotech #precisionmedicine #immunology #inflammation
-
-
Today, Triveni Bio's senior management participated in a fireside chat at the Stifel 2024 Virtual Immunology and Inflammation Summit, where they provided key updates on the company's lead program, TRIV-509, along with other pipeline program updates.?Watch a replay of the webcasted presentation here: https://lnkd.in/ejau5eQp
-
Happy to share that our redesigned website is live! Explore our team, culture, science and pipeline at the new www.triveni.bio.
-
We are thrilled to welcome Dr. Bhaskar Srivastava, M.D., Ph.D., Triveni’s new Chief Medical Officer! He arrives at a key moment of growth and evolution for the company as we advance our lead program, TRIV-509, into the clinic in the first half of 2025. Dr. Srivastava’s extensive training as a dermatologist and immunologist will further our goal of driving much needed innovation for I&I diseases. Learn more about today’s announcement here: https://bit.ly/3KHxJLC #Inflammation #Immunology #Dermatology #Innovation #Biotech
-
Exciting news from Triveni Bio after a busy week! Jennifer Dovey, our CSO, delivered an oral presentation on TRIV-509 at the Society for Investigative Dermatology’s 2024 Annual Meeting. The presentation focused on the promising results of TRIV-509 in atopic dermatitis models, demonstrating its ability to ameliorate barrier dysfunction, inflammation, and itch. Jennifer and Eva Asp, VP of Biology, also presented a poster covering the oral data in detail. Brantley Herrin, VP of Biologics, and Ye Tang, Sr. Scientist, Biologics, presented a poster on TRIV-509, our dual-specific antibody targeting KLK5 and KLK7 proteases at the PEGS 2024 Essential Protein & Antibody Engineering Summit. The poster highlighted TRIV-509's high-affinity binding at the active sites of each protease, effectively inhibiting the proteolytic activity of both. These presentations showcase the potential of TRIV-509 as a novel treatment for atopic dermatitis patients and beyond.?
-